3-fluorophenylguanidine nitrate | 65783-20-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-fluorophenylguanidine nitrate
• 英文别名: 1-(3-fluorophenyl)guanidinium nitrate；N-(3-Fluorophenyl)guanidine nitrate；2-(3-fluorophenyl)guanidine;nitric acid
• CAS: 65783-20-2
• 化学式: C₇H₈FN₃*HNO₃
• 分子量: 216.172
• InChiKey: PUARUQQLDPRZGV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.38
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  130
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-[(二甲基氨基)亚甲基]-1,3-环己二酮 、 3-fluorophenylguanidine nitrate 在 三乙胺 作用下， 以 乙醇 为溶剂， 以51%的产率得到2-((3-fluorophenyl)amino)-7,8-dihydroquinazolin-5(6H)-one
  参考文献：
  名称：

  Discovery, synthesis, and structure–activity relationships of 2-aminoquinazoline derivatives as a novel class of metabotropic glutamate receptor 5 negative allosteric modulators

  摘要：

  A virtual screening approach using various in silico methodologies led to the discovery of 2-(m-tolylamino)-7,8-dihydroquinazolin-5(6H)-one (1) as a moderately active negative allosteric modulator (NAM) of the metabotropic glutamate receptor subtype 5 (mGluR5) showing high selectivity against the subtype mGluR1. Modifications of the parent compound by rational design yielded a series of highly potent derivatives which will serve as valuable starting points for further hit-to-lead optimization efforts toward a suitable drug candidate for the treatment of L-DOPA induced dyskinesia. (c) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.06.049
• 作为产物：
  描述：

  间氟苯胺盐酸盐 在 硝酸铵 作用下， 以 乙醇 、 水 为溶剂， 反应 6.0h， 生成 3-fluorophenylguanidine nitrate
  参考文献：
  名称：

  芳基胍对5-羟色胺-3（5-HT 3）亚基A受体的超激动剂，完全激动剂，部分激动剂和拮抗剂作用。

  摘要：

  对芳基胍基5-羟基色胺3（5-HT 3）受体配体的取代模式进行微小变化的引入导致了从拮抗剂到超激动剂的各种各样的功能活性配体。例如，（ⅰ）引入附加氯取代基（一个或多个），以提供引线完全激动剂的ñ - （3-氯苯基）胍（米CPG，2 ;功效（％）= 106），得到超级激动剂7 - 9（效力（％）= 186 （分别为139和129），（ii）2的位置异构体，p -Cl类似物11，表现出部分激动剂作用（功效％= 12），以及（iii）在间位取代卤素原子或对位具有给电子OCH位置3基团或更强的吸电子（即，CF 3）基团导致拮抗剂13 - 16。我们结合诱变，晶体学和计算分析得出结论，对于5-HT 3受体，芳基胍能更好地同时与一级亚基和互补亚基结合，从而使它们紧密接近，而具有更高的激动剂特性。缺乏这种能力的是拮抗剂。

  DOI：

  10.1021/acschemneuro.6b00196

文献信息

• [EN] IMIDAZO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS<br/>[FR] DÉRIVÉS D'IMIDO-THIAZOLE EN TANT QU'INHIBITEURS DE PROTÉINES KINASES
  申请人：ABBOTT LAB

  公开号：WO2009070516A1

  公开（公告）日：2009-06-04

  Compounds of formula I that inhibit protein kinases, compositions containing the compounds and methods of treating diseases using the compounds are disclosed. Formula I and therapeutically acceptable salts, prodrugs and salts of prodrugs thereof, wherein X is CH or N; A1 is R1, OR1. NHR1, N(R1)2, NHC(O)R1, NHC(O)NHR1, NHC(O)N(R1)2, NHC(O)OR1, C(O)NHR1, C(O)N(R1)2, C=NOR1, or C(NH2)NOC(O)R1;

  公开了抑制蛋白激酶的化合物I的公式，包含这些化合物的组合物以及使用这些化合物治疗疾病的方法。公式I及其治疗上可接受的盐，前药和前药的盐，其中X为CH或N；A1为R1，OR1，NHR1，N(R1)2，NHC(O)R1，NHC(O)NHR1，NHC(O)N(R1)2，NHC(O)OR1，C(O)NHR1，C(O)N(R1)2，C=NOR1或C(NH2)NOC(O)R1。
• 2-Pyrimidinyl Pyrazolopyridine Erbb Kinase Inhibitors
  申请人：Uehling Edward David

  公开号：US20080051395A1

  公开（公告）日：2008-02-28

  The present invention provides 2-pyrimidinyl pyrazolopyridine compounds, compositions containing the same, as well as processes for the preparation and their use as pharmaceutical agents.

  本发明提供了2-嘧啶基吡唑吡啶化合物，含有这些化合物的组合物，以及其制备过程和作为药物剂的用途。
• Novel Synthesis of<i>N</i>-Phenyl-2-aminopyrimidine Derivatives under Solvent-Free Conditions
  作者：Ivaylo Elenkov、Davor Kidemet、Vesna Prgomet

  DOI：10.1055/s-2005-917074

  日期：——

  An efficient method for the solvent-free synthesis of N-phenyl-2-aminopyrimidines has been developed through cyclocondensation of N-phenylguanidine with enaminone in the presence of DBU. The procedure is experimentally simple with very short reaction times and good yields. According to this procedure a variety of N-phenyl-2-aminopyrimidines were synthesized.

  通过在DBU存在下，N-苯基胍与烯丙酮环缩合，已开发出一种无溶剂合成N-苯基-2-氨基嘧啶的有效方法。该方法实验简单，反应时间短，收率高。根据该方法，已合成了多种N-苯基-2-氨基嘧啶。
• PROTEIN KINASE INHIBITORS
  申请人：Ba-Maung Nwe Y.

  公开号：US20090253723A1

  公开（公告）日：2009-10-08

  Compounds that inhibit protein kinases, compositions containing the compounds and methods of treating diseases using the compounds are disclosed.

  本文公开了抑制蛋白激酶的化合物，含有这些化合物的组合物以及使用这些化合物治疗疾病的方法。
• 2-Anilino-4-(thiazol-5-yl)pyrimidine CDK Inhibitors:  Synthesis, SAR Analysis, X-ray Crystallography, and Biological Activity
  作者：Shudong Wang、Christopher Meades、Gavin Wood、Andrew Osnowski、Sian Anderson、Rhoda Yuill、Mark Thomas、Mokdad Mezna、Wayne Jackson、Carol Midgley、Gary Griffiths、Ian Fleming、Simon Green、Iain McNae、Su-Ying Wu、Campbell McInnes、Daniella Zheleva、Malcolm D. Walkinshaw、Peter M. Fischer

  DOI：10.1021/jm0309957

  日期：2004.3.1

  Following the identification through virtual screening of 4-(2,4-dimethyl-thiazol-5-yl)pyrimidin-2-ylamines as moderately potent inhibitors of cyclin-dependent kinase-2 (CDK2), a CDK inhibitor analogue program was initiated. The first aims were to optimize potency and to evaluate the cellular mode of action of lead candidate molecules. Here the synthetic chemistry, the structure-guided design approach, and the structure-activity relationships (SARs) that led to the discovery of 2-anilino-4-(thiazol-5-yl)pyrimidine ATP-antagonistic CDK2 inhibitors, many with very low nM K(i)s against CDK2, are reported. Furthermore, X-ray crystal structures of four representative analogues from our chemical series in complex with CDK2 are presented, and these structures are used to rationalize the observed biochemical SARs. Finally results are reported that show, using the most potent CDK2 inhibitor compound from the current series, that the observed antiproliferative and proapoptotic effects are consistent with cellular CDK2 and CDK9 inhibition.